The rates of endocytosis, intracellular degradation, and cell-surface shedding of 1261-labeled monoclonal antibodies (MoAbs) HD-37 (anti-CD1 9). B1 (anti-CDPO), MB-l (anti-CD37). BC8 (anti-CD45). and DA4-4 (anti-p) by B-lymphoma cells were compared by cellular radioimmunoassay, ultrastructural autoradiography, sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and thin layer chromatography using biopsy specimens from 1 2 patients with non-Hodgkin's lymphomas. 1261-BC8 was stably retained on the surface of lymphoma cells without appreciable internalization or shedding, whereas 12%DA4-4 underwent rapid endocytosis and degradation.
internalized or degraded by tumor cells, but rapidly dissociated from the cell surface in intact form. Moderate rates of endocytosis, intracellular metabolism, and cell-surface shedding were shown by 12%HD37 and 1261-MB-1. The 3 patients with diffuse, small cleaved-cell lymphomas internalized and degraded antibodies more slowly than did patients with other histologic subtypes. These kinetic differences may be important in the selection of MoAbs for immunotoxin and radioimmunoconjugate therapy of B-cell malignancies.
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marked variation among the antibodies in their rates of internalization, deiodination, and dissociation from the cell surface. Antibodies recognizing CD1 9 (HD-37), CD20 (B I), CD37 (MB-l), and CD45 (BC8) were chosen for study because of the reliability of their reactivity with human B-cell malignancies.' As a prototype of a rapidly internalized antibody, we used an anti-g MoAb (DA4-4) even though its in vivo therapeutic potential is limited by its reactivity with circulating IgM. These studies showed a wide spectrum of antibody behavior. 12'1-BC8 was stably retained on the surface of lymphoma cells without appreciable endocytosis or shedding, whereas "'I-DA4-4 was rapidly internalized and degraded to small molecular weight fragments that were subsequently exocytosed by tumor cells. I2'I-BI was not internalized or degraded by tumor cells, but was rapidly shed from the cell surface in intact form. I2'I-HD37 and '*'I-MBl showed moderate rates of endocytosis, intracellular metabolism, and cell-surface shedding. These kinetic differences may be important in the selection of MoAbs for immunotoxin and radioimmunoconjugate therapy of B-cell malignancies.
MATERIALS AND METHODS
Anlibodies. Antibodies studied included anti-CD45 MoAbs BC8 and 9.4 (from Drs Claudio Anasetti and Paul Martin, respectively; Fred Hutchinson Cancer Research Center, Seattle, WA); antihuman IgM (p-chain) MoAbs DA4-4 (from the American Type Culture Collection, Bethesda, MD), BUI, and CH6 (from The Binding Site, Birmingham, UK); anti-CD19 MoAbs HD37 (from Dr Ellen Vitetta, University of Texas at Dallas, Dallas, TX), B4 (Coulter Immunology, Miami, FL), and SJ25-C I (from Caltag Laboratories, South San Francisco, CA); anti-CD20 MoAbs B1 (from Dr Stephan Glenn, Coulter Immunology) and I F5 (from Dr Jeffrey Ledbetter, Bristol-Myers/Squibb, Seattle, WA); anti-CD37 MoAb MB-I (from Dr Richard Miller, Idec Pharmaceuticals, Mountain View, CA); and control MoAb MOPC-21 (from Sigma Chemical CO, St Louis, MO). MoAbs were purified from ascitic fluid or hybridoma culture supernatants by affinity chromatography on Sepharose-Staphylococcal protein A* or by ion-exchange chromatography. Protein concentrations were determined using the BCA assay following the recommendations ofthe manufacturer (Pierce Chemical CO, Rockford, IL). Salient features of the MoAbs are summarized in Tables 1 and 2 .
Cellsuspensions. Fresh lymphoma cells were obtained from diagnostic biopsies performed on 12 patients with relapsed B-cell lymphomas presenting to the University of Washington Medical Center (Seattle, WA) after obtaining informed consent. Ofthe 12 patients, For personal use only. on November 11, 2017. by guest www.bloodjournal.org From 7 had low-grade NHLs (including 6 follicular small cleaved-cell lymphomas and I mantle zone lymphoma), and 5 patients had intermediate-grade lymphomas (3 diffuse small cleaved-cell; 1 diffuse mixed, small cleaved-and large-cell; and 1 follicular large-cell lymphoma). Single cell suspensions were made by mincing lymph node fragments and by pressing the cells through wire screens. After removing cell debris by sedimentation, cells were either studied fresh or were stored in 10% dimethyl sulfoxide and 90% fetal calf serum (FCS) in liquid nitrogen until analyzed. These studies were approved by the Human Subjects Committee of the University of Washington (Seattle).
Malignant B-(Daudi, Raji, Ramos) and T-(Jurkat) lymphoma cell lines were maintained in log-phase growth in RPM1 1640 medium supplemented with 12% FCS, 2 mmol/L glutamine, and l mmol/L pyruvate at 37°C in 5% carbon dioxide.
Microfluorimetry. The binding of MoAbs to target cells was determined by indirect immunofluorescence using a fluoresceinated goat antimouse Ig reagent (FITC-GAMIg; TAG0 Inc, Burlingame, CA). Cells were incubated for 30 minutes on ice with MoAbs at saturating concentrations, washed, then incubated with a I :20 dilution of FITC-GAMIg, washed, and then fixed with I% paraformaldehyde. Cells were then analyzed on a cell sorter (Facstar; Becton Dickinson Inc, Sunnyvale, CA).
Radioiodination. MoAbs were labeled with lZ5l-Na by the IodoGen method. MoAb (100 pg) was incubated with 0.5 mCi of lz5I-Na in glass tubes coated with 10 pg of Iodogen (Pierce Chemical CO) for IO minutes at room temperature. Free lz5I-Na was removed by chromatography on a Pharmacia PD-IO column (Pharmacia, Piscataway, NJ). Eluted fractions containing 12s1-labeled antibody were pooled and stored at 4°C. The immunoreactivity (proportion of antibody molecules in a preparation that was capable of binding to antigen) and avidity of radiolabeled MoAbs were determined using a Burkitt's lymphoma cell line (Daudi) at room temperature (22°C) by the displacement method of Munson and Rodbard using the LIGAND computer program. ' Endocytosis assay. Human lymphoma cells were washed in cold serum-free RPM1 1640 and pelleted by centrifugation. '"I-labeled MoAbs were added to the cell pellets in a ratio of 200,000 cpm (30-45 ng protein) per IO6 cells in a volume of 0.5 mL. Nonspecific binding was assessed by blocking lymphoma cells with a 100-fold excess of "cold" (uniodinated) antibody before exposure to 1251-MoAbs, by using Jurkat T cells, and by using irrelevant MoAb MOPC2 1. Cells were incubated with 1Z51-MoAbs at 4°C for 1 hour and then washed twice with cold RPM1 1640. Aliquots containing 1 X IO6 cells were plated in 200 pL RPM1 1640 in microtiter plates (Flow Laboratories), warmed to 37°C (in a humidified CO2 incubator) for various time intervals, and then assayed for radioactioactivity in the supernatant, surface membrane, and intracellular compartments as described below.
Following 0. I , 4, 18, and 24 hours of culture, cell suspensions were pelleted by centrifugation at 4°C at 300g for 3 minutes. Supernatants were aspirated, and the radioactivity was determined on a Beckman Gamma 5500 Counter (Beckman Instruments, Palo Alto, CA). Surface-bound antibody was then removed from cell membranes using two consecutive 15-minute acid washes (pH 2.0). Cells were sedimented by centrifugation (300g) and subjected to a second acid wash. The two acid washes were pooled, and the radioactivity eluted wasdetermined by gammacounting. This technique released 290% of the cell-associated radioactivity from cells labeled with '251-antibodies, when cell suspensions were maintained at 0 to 4°C to inhibit endocytosis. Nonspecific binding of labeled MoAbs to cells lacking the target antigen represented less than I% of the radioactivity bound to the cells expressing the antigen. After stripping of surface 1251-MoAbs and collecting the acid washes, the cell pellets were harvested from microwells with cotton swabs. Cell pellets were assessed for the presence of internalized ("acid-resistant") '"1-MoAbs by gamma counting.
Antibody degradation. The extent of degradation of the lz5I-MoAbs was measured as previously d e~c r i b e d .~~'~ Culture supematants (0.2 mL) were mixed with 0.6 mL of 25% trichloroacetic acid (TCA) to precipitate protein-bound lz5I released from the cell surface. Precipitates were washed with 0.5 mL 25% TCA, and the radioactivity in the pellets and washes was determined.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. To assess the catabolism of internalized 1251-MoAbs, cells were solubilized in 0.1% NP40 after various periods of incubation at 37T, then mixed with protease inhibitors (leupeptin, 0.05 mg/mL; aprotonin, 0.02 mg/mL; pepstatin, 0.07 mg/mL; and phenylmethylsulfonyl fluoride, 4 mmol/L), centrifuged at 10, OOOg to remove insoluble material, mixed I:I with sample buffer, boiled, and loaded onto 15% polyacrylamide gels containing 0.08% bisacrylamide. Electrophoresis was performed according to the method ofLaernm1i.l' Autoradiographs were made by exposing processed radioactive gels to Kodak X-omatic film (Eastman Kodak, Rochester, NY) in holders equipped with DuPont Cronex intensifying Screens (DuPont CO, Wilmington, DE).
Thin layer chromatography. The radioactive molecular species present in the acetone-soluble portion of cell culture supernatants were characterized by thin layer chromatography (TLC) by the method of Geis~ler.'~ Control experiments showed that TCA-soluble and acetone-soluble counts per minute (cpm) were eq~ivalent.'~ Acetone precipitation was used for TLC because TCA destroyed the polyamide TLC plates.
Immunoelectron microscopy and autoradiography. Autoradiographic electron microscopy of lymphoma cells was performed to determine the intracellular location of internalized '251-MoAbs as a function of time. Lymphoma cell suspensions ( 5 X lo6 cells per sample) were incubated with saturating concentrations of "' IMoAbs at 4°C for 45 minutes, washed twice, and then incubated at 37°C for 0, I , 4, 18, and 24 hours before fixing in 2% glutaraldehyde and 2% paraformaldehyde in 0. I mol/L cacodylate (pH 7.4) at 4°C for 30 minutes, washing in 0.1 mol/L cacodylate, and postfixing in 1% osmium tetroxide for 45 minutes. Cells were pelleted in 1% low melting point Agarose (Bethesda Research Laboratories, Gaithersburg, MD) at 37T, cooled, dehydrated in graded ethanol, embedded in Epon, sectioned, and placed on 200-mesh copper grids (Ted Pella Inc, Redding, CA). Grids were then coated with Ilford L4 nuclear emulsion (Polysciences, Warrington, PA), exposed for 1 month at 4"C, developed in Kodak D-l9 developer (Eastman-Kodak), and counterstained with lead citrate. Sections were examined using a Phillips 201 transmission electron microscope (Mahwah, NJ) operated at 60 kV.
RESULTS

Antigen density on lymphoma cells. The relative densities of the B-cell surface antigens recognized by MoAbs
and DA4-4 (p) on patient lymphoma cells were determined using indirect immunofluorescence. Data from the fluorescence histograms for each antibody were averaged for the 12 patients, and composite fluorescence histograms were plotted (Fig l) . The average flow cytometer channel numbers at which the modal fluorescence intensity (MFI) was observed for each antibody are shown in Table 1 with the observed ranges and standard deviations. Although individual patient variability in antigen expression was observed, all five pan-B antibodies were expressed at high density on nearly all tumors. In general, CD45 and CD37 were expressed at HD37 (CD19), B1 (CD20), MB-1 (CD37), BC8 (CD45), slightly higher antigen densities in these patients than CD 19, CD20, and surface IgM (Fig 1 and Table I) .
Antibody avidities. Antibody internalization and metabolism. The retention of radioimmunoconjugates by tumor cells after initial binding is dependent on the rates of passive shedding of "' 1-MoAbs from the cell surface (detectable as TCA-precipitable radioactivity in culture supernatants) and of antibody endocytosis and metabolism (measured as release of TCAsoluble radioactivity to culture sup ern at ant^).'.^^ We used a previously described cellular radioimmunoassay to quantitate the percent of initially bound IZ5I-MoAb retained by patient lymphoma cells :S a function of time in culture at 37T, as well as the percent shed to the supernatant (as TCAprecipitable cpm) or secreted from cells after intracellular catabolism (TCA-soluble cpm). The results observed for all patients were averaged and plotted (Figs 2, 3, and 4). Negligible catabolism of "'I-B1 and "'I-BC8 was observed (4% f 2% and 2% rt 1 %, respectively, of initially bound cprn were released to the supernatants as TCA-soluble cprn after 24 hours). In contrast, cells labeled with "'1-DA4-4 released 49% * 5% of initially bound cpm to the culture medium as small molecular weight, TCA-soluble species within 19 hours (Fig 2) . Cells labeled with "'I-HD37 and lZ'I-MB-l catabolized 7% f 4% and 16% * 4%, respectively, of bound radioactivity within 24 hours (Fig 2) . Prominent shedding of TCA-precipitable Iz5I-MoAbs from the surface of lymphoma cells was observed with anti-CD20 antibody B 1 and anti-CD19 antibody HD37 (52% * 3% and 47% f 3% shed, respectively, in 24 hours; Fig 3) . Lower rates of shedding were observed with anti-CD37 MoAb MB-l (28% f 4%), anti-p MoAb-DA4-4 (20% rt S%), and anti-CD45 MoAb BC8 (1 2% t 2%) (Fig 3) . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that almost all of the TCA-precipitable supernatant radioactivity was undegraded (molecular weight, 150 kD), and rebinding experiments showed that shed antibody was still immunoreactive (data not shown). No evidence for antigen shedding was found for any of the MoAbs by SDS-PAGE analysis.
Radioactivity was retained best by lymphoma cells labeled with '''I-BCS (86% f 1% of initially bound cpm retained after 24 hours) and worst by lZ5I-DA4-4-labeled cells (30% f 7% at 19 hours; Fig 4) . Analysis of the location of cell-associated radioactivity using surface membrane strip ping with low pH washes showed that the majority of cellassociated "'1-DA4-4 was intracellular (54% * 4% after just l hour), whereas most of the radioactivity for the other antibodies was located on the surface membrane (86% to 94% at 1 hour and 75% to 87% after 24 hours).
In general, the rates of endocytosis and degradation varied little from patient to patient for any given antibody, as shown by the narrow standard error bars in Figs 2 through 4. The only significant kinetic heterogeneity involved a trend for slower rates of internalization and degradation of Iz5I-DA4-4, "'I-MB-l, and "'I-HD37 by the 3 patients with diffuse, small cleaved-cell lymphomas and the patient with follicular large-cell lymphoma. Cells from these 4 patients degraded an average of 6% + 3% of "' 1-MB-1 to TCA-soluble metabolites in 24 hours, compared with an average of 22% t 5% (P = .02) degradation in the same time period by the other 8 patients. Similar trends for decreased internalization and degradation of lZ'I-HD37 and I2'I-DA4-4 and hours for the presence of TCA-precipitable supernatant radioactivity. Data for all patients were averaged and plotted as the percentage of initially bound cpm released in TCA-precipitable form.
-" . antibody (150 kD, Fig 5) , consistent with the absence of internalization and degradation seen in cellular radioimmunoassays with these antibodies (Fig 2) .
Analysis of the acetone-precipitable, high-molecularweight fraction of culture supernatants with SDS-PAGE showed that the only radioactive high-molecular-weight species released from cells incubated with any of the MoAbs was intact antibody ( 1 50 kD; data not shown). The intermediate-molecular-weight species observed in cell lysates of '"I-HD37, MB-I, and DA4-4 were not released to the supernatant until degraded further to small-molecular-weight, acetone-soluble species. Analysis of the acetone-soluble fractions ofthe supernatants of cells labeled with "'I-HD37, MB-1, and DA4-4 for 24 hours by TLC showed two species, 1251-tyrosine (92% to 99% of radioactivity) and free 1251 (2% to 8% of radioactivity; data not shown). The amounts of acetone-soluble radioactivity in cultures of "'I-BI-and Iz5I-BC8-labeled cells were too low for analysis.
Ultrastructural autoradiography. Morphologic assessment ofthe subcellular location of 1251-MoAbs was provided by autoradiography at the electron microscopic level. Patients' lymphoma cells were surface-labeled with saturating concentrations of 1251-MoAbs, washed, and incubated at 37°C for 0 to 24 hours before fixing and processing for electron microscopy and autoradiography. At time Q, all autoradiographic silver grains were intimately associated with the cell surface membrane for all 1251-MoAbs. (Fig 6A) . Strict localization of antibody to the surface membrane was observed at all time points (0 to 24 hours at 37°C) for lymphoma cells labeled with 12'I-Bl or 1251-BC8 (Figs 6C and  D) . In contrast, nearly all silver grains in 1251-DA4-4-labeled cells were located over endosomes or lysosomes after 4 to 24 hours of incubation at 37°C (Fig 6B) . Lymphoma cells labeled with 12'I-MB-I and 129-HD37 showed mixed patFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From
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formed with all I I MoAbs showed that the curves for total cell-associated radioactivity, cell surface radioactivity, intracellular radioactivity, supernatant radioactivity, antibody shedding (TCA-precipitable supernatant radioactivity), and antibody degradation (TCA-soluble supernatant radioactivity) were similar for all antibodies targeting a given antigen. Space does not permit full exposition of these results, but Table 2 summarizes the rates of appearance of TCA-soluble cpm in the supernatant of cells surface-labeled with 1-125-DA4-4, CH6, BU I , HD37, B4, SJ25-C11 B1, I F5, and BC8. Although some individual antibody variation was observed, all 3 anti-lgM antibodies were rapidly internalized and degraded (39% to 60% of total cpm were released to the supernatant in TCA-soluble form within 24 hours). The 3 anti-CD1 9 antibodies showed degradation rates varying from 1 1% to 4 I% in 24 hours (Table 2 ), whereas none of the 4 anti-CD20 or anti-CD45 antibodies were appreciably metabolized ( 4 % TCA-soluble cpm in 24 hours). These findings are consistent with those depicted in Figs 2 through 4. The modest variations in the rates of internalization and degradation for different antibodies targeting the same antigen (Table 2 ) may be at least partially caused by differences in isotype (IgGI for BC8 and lgG2a for 9.4), avidities (2 X IOx for BI and 3.7 X IOs for IF5), or epitope recognition. Cross-blocking studies showed that no 2 antibodies bound to the same epitope. There was no cross-blocking between DA4-4 and CH6, and only partial cross-blocking between DA4-4 and BU-I (29% f 6% blocking). HD37 partially cross-blocked B4 (55% ? 9% blocking) and SJ25-Cl (63% f 12% blocking), whereas B I partially cross-blocked 1 F5 (30% f I % blocking).
DISCUSSION
Several variables appear to interact in a complex manner to determine the cytotoxicity of immunoconjugates for tumor cells.'-4 Many studies have investigated parameters that influence the biodistribution of radiolabeled antibodies within the body and the homogeneity ofdistribution within tumor masses (ie, antibody size [IgM, intact IgG, F(ab')z, Fab'], antibody avidity,13 conjugate chemistry [chelates vradioiodinated antibodies], tumor ~ize,'~.'' ~plenomegaly,'~.'~ and tumor vascularity"). However, the parameters that affect the retention of radioimmunoconjugates at tumor sites after initial binding to cancer cells have been less well studied. Prior investigations that have studied the fate of radiolabeled MoAbs have been limited to tumor cell conduct an in depth analysis of the rates of endocytosis, intracellular degradation, and passive dissociation of radioiodinated MoAbs targeting actual human lymphoma cells. In addition, by studying a number of fresh tumor specimens, we were able to make some preliminary observations concerning the variability between different lymphoma types. terns of surface and intracellular localization of silver grains (data not shown).
Comparative anal-vsis of other antibodies targeting p, CD19, CD20. and CD45. It was important to determine whether the patterns of internalization and degradation observed for the five antibodies described above were antigenspecific or idiosyncratic. To address this question, we compared our 5 prototype antibodies with 6 others: 2 targeting surface IgM (CH6, BUI), 2 bindingtoCD19 (B4, SJ25-CI), 1 binding to CD20 (IF5), and 1 directed against CD45 (MoAb 9.4; data provided by Dr Paul Martin [Fred Hutchinson Cancer Research Center, Seattle, WA]). We were unable to obtain another anti-CD37 MoAb. Because of limitations in the supply of fresh lymphoma cells, these experiments were performed using the Ramos Burkitt's lymphoma cell line. Cellular radioimmunoassays per- body that is known to be rapidly internalized and degraded by tumor cells.l'.'x In addition. the behavior of DA4-4 was ofinterest because ofthe widespread use ofanti-p antibodies for studies of B-cell activation.'5 and of anti-lg idiotypic antibodies for tumor therapy.'h The results of our studies on these antibodies afford insights into the rational selection ofantibodies for immunotoxin and radioimmunoconjugate trials of human hematopoietic malignancies, as discussed below.
Retention of "'1-MoAbs by tumor cells after initial cell binding is dependent on the kinetics of two separate processes, namely, ( I ) endocytosis and intracellular degradation of "I-MoAbs with exocytosis of small catabolites to the interstitial fluid and (7) passive dissociation or shedding of intact "'I-MoAb from the cell surface to the interstitial fluid. These processes were studied by four complementary techniques: cellular radioimmunoassay, ultrastructural autoradiography. SDS-PAGE analysis, and TLC. These methods showed a spectrum in the rates of endocytosis and deg- lines than by the patients' cells (Table 2 and Fig 2) . Comparative analysis of six other MoAbs targeting p, CD 19, CD20,  or CD45 showed general concordance in the behavior of all antibodies within an antigen group, although some variability was observed, particularly with anti-CD 19 MoAbs. Recent evidence from another laboratory suggests that the rates of internalization of anti-CD 19 MoAbs may be modulated by i~otype.'~ In that study, IgGl anti-CD19 MoAbs were internalized more rapidly by FcyRII-positive tumor cells (eg, Daudi cells) than were IgG2a MoAbs, which were unable to interact with the FcyRII re~eptor.~' Passive shedding of intact undegraded, "'1-MoAbs was rapid and extensive for the lower avidity I2'I-Bl and I2'I-HD37 MoAbs (52% and 47% shed in 24 hours, respectively), but was much less rapid for the higher avidity 1251-MB-I MoAbs and 12'I-DA4-4 (8% to 29% shed in 24 hours). '*'I-BC8 behaved somewhat aberrantly, being retained by tumor cells much more tightly than would be expected from its avidity constant ( Table 1 ). This observation emphasizes that avidity measurements, as commonly performed, represent a ratio of two separate processes, namely, the rate of cell association (Ka) and the rate ofdissociation (Kd).28 BC8 has a moderate overall avidity, but an extremely low rate of dissociation.
Our results showed that cells from 8 of the 12 patients internalized and metabolized each of the five antibodies with kinetics similar to those previously reported for tumor cell line^?"^^^ Cells from the other 4 patients appeared to internalize and degrade one or more of the "internalizing" antibodies ( "'I-DA4-4, I2'I-MB-l, and I2'I-HD37) more slowly than did either Daudi cells' or cells from the other 8 patients, although this trend only reached statistical significance for 1251-MB-l. All 4 of these lymphomas were intermediate grade (3 diffuse, small cleaved-cell and 1 follicular large-cell lymphoma), suggesting that slower antibody endocytosis and degradation might be a common feature of this histologic grade. Further studies with more patients will be necessary to determine the possible significance of this observation. However, in general, the Daudi and Ramos Bcell lines appear to serve as acceptable models for the antibody-handling behavior of human lymphomas.
Certain therapeutic conclusions can be drawn from these studies. First of all, noninternalizing MoAbs such as B I and BC8 should not be effective as immunotoxins, because delivery of toxins such as ricin A chain or Pseudomonas exotoxin to intracellular target sites will not occur. This prediction has already been verified by several groups for anti-CD20 antibodies3' Conversely, the same noninternalizing antibodies should be excellent choices for 13'1 radioimmunotherapy, because they will be resistant to intracellular degradation and deiodination. Again, clinical corroboration for this hypothesis is a~a i l a b l e . '~~~'~~' However, caution must be exercised to avoid over-extrap olation of these kinetic observations to the selection of anti-B-cell MoAbs for therapeutic immunoconjugate trials. Firstly, internalization alone is not the sole determinant of immunotoxin efficacy. HD37 makes a potent ricin A chain immunotoxin,20 despite a modest endocytosis rate (Fig 3) , presumably because of effective intracellular routing of the fraction of internalized immunotoxin to cytosolic ribosomes. The importance of epitope binding in determining intracellular routing of immunotoxins after endocytosis has been previously reported." Secondly, many in vivo parameters affecting antibody-conjugate efficacy are not assessable by the in vitro assays used in this report. For instance, I3'I-Bl has been shown to be superior to 13'I-MB-I for radioimmunotherapy, in spite of similar rates of tumor cell retention (Fig  4) , because of lesser infusional toxicity, less binding to non-B-cells, and a longer serum half-life.I4 In addition, the lower avidity of B1 may result in better penetration into tumor sites than that for MB-1 because of less trapping of B 1 by perivascular antigen-binding cells ("the binding site barrier""). Similarly, enthusiasm for I3'I-BC8 as a radioimmunotherapeutic reagent based . m its superlative cell surface retention (Fig 4) must be tempcred by the knowledge that CD45 is expressed on all hematopoietic cells and might, therefore, be substantially more toxic than more specific antibodies.
Our preclinical and clinical experiments, in combination with those of other worker^,^,'^,'^.^'.^' suggest that the ideal MoAb for '3'I-radioimmunotherapy should show a high degree of specificity for B cells, a slow antigen association rate (to minimize the "binding site barrier" phenomenon"), a slow dissociation rate (to maximize retention to tumor cells after binding), and a negligible endocytosis rate (to minimize intracellular degradation and release of low molecular weight '3'I-catabolites). Conversely, we hypothesize that the ideal MoAb for in vivo immunotoxin therapy should possess a high degree of B-cell specificity and slow antigen association and dissociation rates, but should undergo rapid endocytosis and routing to cytosolic ribosomes. These hypotheses should be testable by analysis of mutant clones derived from anti-CD19 and anti-CD20 hybridomas (for immunotoxin and radioimmunoconjugate studies, respecFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From
